Research Articles

GLP-1 Receptor Agonism Explained: Molecular Mechanism Deep Dive

Deep dive on GLP-1 receptor agonism — binding affinities, signaling cascades, GIP/GLP-1 dual agonism, and triple-agonist research from 2024–2026 literature.

Read article →Article

SURMOUNT-1 Trial Deep Dive: Tirzepatide Phase 3 | Artemis Labs

Detailed analysis of the SURMOUNT-1 phase 3 tirzepatide trial — 72-week efficacy data, ~20.9% mean weight reduction, safety profile, and 2026 research implications.

Read article →Article

Weight Loss Research Peptides 2026 | Artemis Labs

Pillar guide to weight loss research peptides — tirzepatide, retatrutide, cagrilintide, AOD-9604, 5-Amino-1MQ — with 2024-2026 trial data and comparative mechanisms.

Read article →Article

Retatrutide Quality Crisis: 37 Samples Failed Testing | Artemis Labs

Independent re-testing documented ~47% retatrutide failure rates across the 2025–2026 market. How to verify your batch and what real third-party testing requires.

Read article →Article

Tirzepatide vs Retatrutide: Mechanism & Efficacy 2026 | Artemis Labs

Side-by-side comparison of tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple) — efficacy, mechanism, safety, and research selection criteria.

Read article →Article

TRIUMPH-4 Retatrutide Trial Design 2026 | Artemis Labs

TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at…

Read article →Article

SLU-PP-332: Exercise-Mimetic ERRα Agonist 2026 | Artemis Labs

SLU-PP-332 ERRα agonist deep dive — mechanism, the 2023 Saint Louis University publication, exercise-mimetic transcriptional signature, and 2024-2026 follow-up research.

Read article →